Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Core Insights - Aclaris Therapeutics has reported positive results from its Phase 2a trial of ATI-2138, an investigational oral covalent inhibitor targeting ITK and JAK3, showing significant improvements in patients with moderate-to-severe atopic dermatitis [1][2][4] Group 1: Clinical Trial Results - Patients receiving a low dose (10 mg BID) of ATI-2138 experienced a 77% improvement in the extent and severity of atopic dermatitis as measured by the Eczema Area and Severity Index (EASI) at the end of treatment (week 12) [4] - Additional improvements included a 70% reduction in the affected percentage of Body Surface Area (BSA), a 50% improvement in Peak Pruritus Numerical Rating Scale (PP-NRS), a 55% improvement in patient-oriented eczema measure (POEM), and a 65% improvement in Dermatology Life Quality Index (DLQI) [6] Group 2: Mechanism and Efficacy - ATI-2138 demonstrated near complete and sustained ITK target occupancy, indicating its high potency and potential for low drug burden and improved tolerability compared to existing JAK inhibitors [4][5] - The compound modulated various immune signaling pathway markers, supporting its broad therapeutic potential in treating immuno-inflammatory diseases [4][7] Group 3: Company Overview - Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, aiming to address unmet medical needs [8]